Corvus: New Data on Solid and Hematologic Cancers at AACR

 Preclinical data supports targeting ITK as a new approach for cancer immunotherapy

Novel mechanism of action modulates T cell differentiation and enhances the immune system via Th1 skewing, increased T cell cytolytic capacity and reduction of T cell exhaustion

Enrollment continues in Phase 1/1b clinical trial of CPI-818 for the treatment of refractory T cell lymphoma, including use of minimum absolute lymphocyte count (ALC) predictive biomarker for patient selection

https://www.biospace.com/article/releases/corvus-pharmaceuticals-presents-new-cpi-818-data-demonstrating-the-potential-of-itk-inhibition-as-a-treatment-for-solid-and-hematologic-cancers-at-the-american-association-for-cancer-research-aacr-annual-meeting/